ArticleNature cancer2023

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

Jessica L Chitty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.